Health utility reporting in chronic rhinosinusitis patients
Adult
Aged, 80 and over
Male
Adolescent
Psychometrics
Health Status
610
Middle Aged
United Kingdom
3. Good health
Young Adult
03 medical and health sciences
0302 clinical medicine
Surveys and Questionnaires
Chronic Disease
Prevalence
Quality of Life
Feasibility Studies
Humans
Female
Prospective Studies
Sinusitis
Aged
Rhinitis
DOI:
10.1111/coa.12903
Publication Date:
2017-05-12T13:54:47Z
AUTHORS (5)
ABSTRACT
AbstractObjectivesDirect comparison of different diseases allows clinicians and researchers to place the burden of symptoms and impact on quality of life of each condition in context. Generic health‐related quality‐of‐life assessment tools allow such analysis, and limited data are available for British patients with chronic rhinosinusitis.DesignAs part of a larger feasibility study, patients underwent baseline assessment using the SNOT‐22, SF‐12 and EQ‐5D‐5L tools. Data were analysed using Microsoft Excel and algorithms available for the analysis of the later two tools. We plotted EQ‐5D‐5L VAS and utility scores and SF‐12 MCS and PCS scores separately against SNOT‐22 scores and quantified associations using bivariate ordinary least squares regression analysis.SettingPatients were prospectively recruited from six UK outpatient clinics.ParticipantsAdult patients with chronic rhinosinusitis without nasal polyps (CRSsNPs).Main Outcome measuresBaseline SNOT‐22, SF‐12 and EQ‐5D‐5L scores.ResultsFifty‐two adults were recruited with a mean age of 55 years, 51% were male. The mean SNOT‐22 score was 43.82. Mental and physical component scores of the SF‐12 were 46.53 and 46, respectively. Mean index score computed form the EQ‐5D‐5L was 0.75. Worse (higher) SNOT‐22 scores were associated with lower EQ‐5D‐5L VAS and utility scores and SF‐12 MCS and PCS scores.ConclusionThe EQ‐5D‐5L suggests that British CRSsNPs patients are negatively impacted with regards to quality of life. We found the SF‐12 to be less sensitive and conclude that the EQ‐5D‐5L tool is a quick and accessible method for assessing QOL in order it can be compared with other disease states.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (25)
CITATIONS (7)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....